Business Daily Media

The Times Real Estate

.

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

  • Written by ACN Newswire - Press Releases

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

TOKYO, Jul 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep

Read more //?#

Why Responsible Leadership is a Competitive Advantage for Small Businesses

In today’s fast-changing business landscape, leadership is evolving. While large corporations are reassessing their diversity, equity, and inclusi...

Why it’s a great time to include the EU in your export push

With the US market beset with unknowns, training your sights on mainland Europe in 2025 makes sound sense. Wondering whether the introduction o...

Success Isn’t About Labels—It’s About Mindset

In the lead up to International Women’s Day, I’ve been reflecting on my own success as a business owner and whether or not being a woman has playe...

Accelerate Action- Thryv champions women in business for International Women’s Day

Thryv® (NASDAQ: THRY), provider of the leading small business software platform, is celebrating International Women’s Day by shining a spotlight o...

Sydney Startup Launches AI Platform To Lead the Charge on Gender Pay Gap Action

EvenBetter.ai launches in Australia with First Customers Knight Frank and Fuji Australia Sydney-based startup EvenBetter.ai has today launched th...

The Real Risk: Why Failing to Plan for Retirement is a Gamble You Can’t Afford

As the CEO of Reventon, I’ve experienced financial ups and downs firsthand. My journey in property investment has been defined by bold decisions, st...

Sell by LayBy